![roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://api.fff1.sbs/article/male2/img/61z3cZ30LoL.jpg)
![roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](https://assets.bwbx.io/images/users/iqjWHBFdfxIU/im9ZIXQJDXo8/v1/-1x-1.webp)
![roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity](http://milkdust.com/cdn/shop/files/glp-1.png?v=1772468312)
Quick Dispatch:
Your roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity ships.
Need Help?
Questions about roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for roche glp-1 Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity in your area.
The next wave of GLP-1 medications could make weight management easier — and more personalized — than ever. Drugmakers like Pfizer, Amgen, Eli Lilly, Roche, Structure Therapeutics, and Novo Nordisk are working
21.04
Roche's Genentech vows to expand NC anti-obesity drug plant
22.21
Roche Announces Positive Topline Results from Phase II Study for Dual GLP-1/GIP Receptor Agonist
28.12
Roche broadens obesity drug plans with $1.65B Zealand deal
29.83
Roche announces positive phase II results for dual GLP-1/GIP receptor
24.32
Roche aiming for 'top 3' position in obesity space as lead asset progresses
28.19
Tirzepatide Weight Loss Injections & Clinics Near You
27.27
